OncoPharm

• BRCA Reversion Mutations

  BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors. Bibliography: 1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-0715 2: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.00933 3: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. https://doi.org/10.1016/j.ccell.2024.10.015

  --------  

  12:43
• HOPA 25 Recap

  Recapping HOPA 25 and Portland *Great food (not discussed, the most excellent ETSU dinner at Arden) *COCOON *Pharmacists make everyone's job easier and keep patients out of the ED *A few more tidbits too!

  --------  

  11:45
• Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview

  FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.

  --------  

  12:25
• Topotecan

  A Foundations of OncoPharm episode on Topotecan. (Originally to be released week of 3/27)

  --------  

  9:46
• API-CAT & IMPROVE

  We discuss reduced dose apixaban for months 6+ of treating cancer-associated VTE (API-CAT) and the impact (or lack thereof) of pausing BTK-inhibitors around vaccination (IMPROVE)

  --------  

  12:42

More Science podcasts

Trending Science podcasts

About OncoPharm